Expertise in
4
conditions

Dr. Milos Miljkovic

Hematology
Sinai Hospital Of Baltimore
2401 W Belvedere Ave, 
Baltimore, MD 
Expertise in
4
conditions
Sinai Hospital Of Baltimore
2401 W Belvedere Ave, 
Baltimore, MD 

Overview

Milos Miljkovic is a primary care provider, practicing in Hematologist in Baltimore, Maryland. Dr. Miljkovic is highly rated in 4 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Myasthenia Gravis, Non-Hodgkin Lymphoma, and Adult T-Cell Leukemia.

His clinical research consists of co-authoring 59 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in MD

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Sinai Hospital of Baltimore
2401 W Belvedere Ave, Baltimore, MD 21215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Enrollment Status: Completed
Publish Date: January 30, 2026
Intervention Type: Diagnostic test, Drug, Procedure
Study Drugs: Romidepsin, Lenalidomide, CC-486, Dexamethasone
Study Phase: Phase 1
Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection
Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection
Enrollment Status: Completed
Publish Date: March 21, 2023
A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: November 04, 2022
Intervention Type: Drug
Study Drugs: CC-486 (5-azacitidine), Duvelisib, Romidepsin, Doxorubicin
Study Phase: Phase 1
A Phase 1 Study of Interleukin-15 in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
A Phase 1 Study of Interleukin-15 in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Biological, Drug
Study Drugs: rhIL-15, Avelumab
Study Phase: Phase 1
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
Enrollment Status: Completed
Publish Date: April 29, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Enrollment Status: Terminated
Publish Date: March 22, 2022
Intervention Type: Biological, Drug
Study Drugs: rhIL-15, Obinutuzumab
Study Phase: Phase 1
View 5 Less Clinical Trials

59 Total Publications

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.
Journal: Nature medicine
Published: October 27, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Taofeek Owonikoko
Hematology | Oncology
Expertise in
18
conditions
Dr. Taofeek Owonikoko
Hematology | Oncology

Office

22 S Greene St # 9, 
Baltimore, MD 
 (4.5 miles away)
410-328-6841
Languages Spoken:
English
See accepted insurances

Taofeek Owonikoko is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Expertise in
34
conditions
Dr. Michael Streiff
Hematology
Expertise in
34
conditions
Dr. Michael Streiff
Hematology

Johns Hopkins Hospital

600 N Wolfe St, 
Baltimore, MD 
 (5.3 miles away)
410-955-3142
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Streiff is a Hematologist in Baltimore, Maryland. Dr. Streiff is highly rated in 34 conditions, according to our data. His top areas of expertise are Venous Thromboembolism (VTE), Deep Vein Thrombosis, Pulmonary Embolism, Pancreaticoduodenectomy, and Bone Marrow Aspiration.

Expertise in
12
conditions
Dr. Patrick Forde
Hematology | Oncology
Expertise in
12
conditions
Dr. Patrick Forde
Hematology | Oncology

Johns Hopkins Bayview Medical Center

4940 Eastern Ave, 
Baltimore, MD 
 (7.5 miles away)
410-550-1711
Languages Spoken:
English
See accepted insurances

Patrick Forde is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Forde is highly rated in 12 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Small Cell Lung Cancer (SCLC).

Frequently Asked Questions about Dr. Milos Miljkovic

How do I make an appointment with Dr. Milos Miljkovic?

You can book an appointment with Dr. Milos Miljkovic by calling their office at 410-601-9386. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Milos Miljkovic a top-rated expert for T-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Milos Miljkovic is classified as an Advanced expert for T-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Milos Miljkovic specialize in?

While Dr. Milos Miljkovic is a Hematology, they have specific expertise in T-Cell Lymphoma, Myasthenia Gravis, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Milos Miljkovic participate in research or clinical trials?

Yes. Dr. Milos Miljkovic has published 59 articles and abstracts on conditions like T-Cell Lymphoma. You can view a list of Dr. Milos Miljkovic's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Miljkovic's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile